Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 13/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 9/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15722709 | 0.85 | AURKA (0.56) | AURKAAURKBNTRK1ITKSRC | |
| SCHEMBL12102876 | 0.82 | MEN1 (0.52) | AURKAAURKBNTRK1ITKSRC | |
| SCHEMBL12105469 | 0.82 | AURKA (0.46) | AURKAAURKBNTRK1ITKSRC | |
| SCHEMBL13060369 | 0.78 | MEN1 (0.37) | AURKAAURKBMEN1KMT2A | |
| SCHEMBL12430805 | 0.74 | AURKA (0.73) | AURKAAURKBNTRK1ITKSRC | |
| SCHEMBL13004410 | 0.72 | AURKB (0.82) | AURKAAURKBSRCGSK3B | |
| SCHEMBL30353136 | 0.70 | JAK2 (0.51) | AURKAAURKBSRCGSK3BMEN1 | |
| SCHEMBL28921761 | 0.69 | ITK (0.43) | AURKAAURKBNTRK1ITKSRC | |
| SCHEMBL8560841 | 0.69 | PKM (0.36) | MEN1HTTKMT2A | |
| SCHEMBL4908609 | 0.69 | IGF1R (0.62) | AURKAAURKBSRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269732-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | AURKA 3/4885AURKB 1/4885NTRK1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.